Palmoplantar pustulosis - Pustulożi Palmoplantarihttps://en.wikipedia.org/wiki/Pustulosis_palmaris_et_plantaris
Pustulożi Palmoplantari (Palmoplantar pustulosis) hija dermatożi pustulari kronika rikorrenti (jiġifieri pustulosi jew psorjasi pustulari) lokalizzata fuq il-pali u l-qigħan biss, ikkaratterizzata istoloġikament minn pustuli intraepidermali mimlija newtrofili. L-użu ta' retinojdi sistemiċi waħedhom u flimkien ma' fotokimoterapija biex itejbu s-sintomi ta' pustulożi palmoplantari (palmoplantar pustulosis) .

○ Trattament
Acitretin orali huwa effettiv għal dan it-tip ta 'psorjasi.
#Acitretin
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
  • F'dan il-każ, pompholyx jista' wkoll jiġi suspettat.
  • Fin-nuqqas ta 'pustuli, ekżema ta' l-idejn tista 'wkoll titqies bħala dijanjosi differenzjali.
References Palmoplantar Psoriasis 28846363 
NIH
Palmoplantar psoriasis huwa tip ta’ psorjasi li prinċipalment taffettwa l-ġilda fuq il-pali u l-pettijiet tiegħek. Jidher bħala ġilda mħaxxna jew xotta, infafet, jew taħlita taż-żewġ tipi.
Palmoplantar psoriasis is a variant of psoriasis that characteristically affects the skin of the palms and soles. It features hyperkeratotic, pustular, or mixed morphologies.
 Tumor Necrosis Factor Inhibitors 29494032 
NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).